Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 20...( Second quarter EPS of $0.44 -- increa...)

Second quarter EPS of $0.44 -- increase of 110% from prior year

EXTON, Pa., Jan. 28 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its second quarter and first six months of fiscal year 2009.

Second Quarter Highlights

• Record EPS of $0.44, representing an increase of 110% from second quarter of prior fiscal year and exceeding previous guidance of $0.40-$0.42.
• EBITDA of $9.3 million, representing an increase of 73% from second quarter of prior fiscal year.
• Operating margin of 37%.
• Operating cash flow of $4.7 million.
• Biomaterial product sales of $13.1 million, representing an increase of 14% from second quarter of prior fiscal year.
• Orthopaedic royalties of $1.4 million, representing an increase of 28% from second quarter of prior fiscal year.
• Completed cartilage preclinical studies; IDE submission for US trial expected in March 2009.
• Accomplished the first milestone under the Spectranetics Research and Development Agreement, completing the development of the next generation Safe-Cross(R) System, which resulted in a $1 million payment to the Company.

First Six Months Highlights

• EPS of $0.87, representing an increase of 142% and 358% from prior fiscal year period earnings per share as adjusted* and as reported, respectively.
• EBITDA of $19.0 million, representing an increase of 92% from prior fiscal year period adjusted EBITDA* (188% from prior fiscal year period EBITDA unadjusted).
• Operating cash flow
  '/>"/>